Logo

AVR

Anteris Technologies Global Corp.

AVR

Anteris Technologies Global Corp. • NASDAQ
$4.10 ▼ -1.68% (-0.07)
Market Cap $134.92 M
52w High $8.79
52w Low $2.34
Dividend Yield 0%
P/E -1.58
Volume 112.47K
Outstanding Shares 32.91M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $429K ▼ $22.571M ▲ $-22.244M ▼ -5.185K% ▼ $-0.94 ▼ $-21.777M ▼
Q2-2025 $618K ▲ $21.354M ▼ $-20.834M ▲ -3.371K% ▲ $-0.89 ▲ $-20.466M ▲
Q1-2025 $556K ▲ $22.129M ▲ $-21.864M ▼ -3.932K% ▼ $-0.93 ▼ $-21.377M ▼
Q4-2024 $536.112K ▼ $21.391M ▼ $-19.375M ▲ -3.614K% ▼ $-0.82 ▼ $-21.114M ▼
Q3-2024 $768.981K $22.212M $-21.859M -2.843K% $-0.61 $-20.229M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $9.119M ▼ $19.074M ▼ $15.715M ▼ $3.698M ▼
Q2-2025 $28.438M ▼ $39.878M ▼ $15.846M ▲ $24.406M ▼
Q1-2025 $48.955M ▼ $58.792M ▼ $15.679M ▼ $43.259M ▼
Q4-2024 $70.458M ▲ $80.699M ▲ $18.017M ▼ $62.761M ▲
Q3-2024 $10.127M $21.102M $18.206M $3.15M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-22.244M ▼ $-18.252M ▲ $-772K ▼ $-294K ▲ $-19.319M ▲ $-19.024M ▲
Q2-2025 $-20.834M ▲ $-19.535M ▲ $-537K ▼ $-442K ▲ $-20.517M ▲ $-20.072M ▲
Q1-2025 $-21.864M ▼ $-21.489M ▼ $1.11M ▲ $-1.091M ▼ $-21.503M ▼ $-21.737M ▼
Q4-2024 $-19.375M ▲ $-18.237M ▼ $-363.568K ▲ $78.4M ▲ $59.84M ▲ $-18.6M ▼
Q3-2024 $-21.794M $-14.101M $-553.064K $18.487M $3.435M $-14.654M

Five-Year Company Overview

Income Statement

Income Statement Anteris looks like a classic early-stage medical device company: almost no product revenue yet, and steady losses driven mainly by research and development and other operating costs. Losses have been growing over time as the company invests more heavily in clinical development and infrastructure. This is normal for a pre-commercial med‑tech firm, but it means the business is still far from self‑funding and depends on outside capital to support ongoing work.

Balance Sheet

Balance Sheet The balance sheet is small but relatively clean. Assets are modest and mostly made up of cash, which has been built up in recent years. The company carries no financial debt, so there is no interest burden or looming repayments. Equity has been increasing as the company raises money to fund operations. However, the overall resource base is still limited relative to its ambitions, so the balance sheet does not provide a large cushion if development takes longer or costs rise.

Cash Flow

Cash Flow Cash flow is consistently negative, reflecting ongoing spending on operations without offsetting revenue. Operating cash outflows and free cash outflows closely match, because capital spending is minimal. In simple terms, the company is burning cash each year to advance its technology and trials, and must periodically refill its cash reserves through funding events such as equity raises. This pattern is typical for a pre‑revenue med‑tech firm but underscores its dependence on capital markets.

Competitive Edge

Competitive Edge Competitively, Anteris is trying to enter a very large, fast‑growing heart valve market dominated by powerful incumbents. Its edge comes from a differentiated valve design, proprietary tissue treatment, and promising early clinical performance that appears more “natural” than existing options. Strong intellectual property and supportive physician involvement add to its emerging moat. At the same time, the company is still small, unproven at scale, and must compete for attention, adoption, and reimbursement against well‑established players with far greater resources.

Innovation and R&D

Innovation and R&D Innovation is the heart of the Anteris story. The DurAVR valve, its specialized tissue treatment process, and the dedicated delivery system together form a tightly integrated platform designed to behave more like a healthy native valve. Early data are encouraging on blood flow and potential durability. The planned large PARADIGM trial is the key next step to validate these claims. Beyond aortic valves, the company is already extending its technology and know‑how into mitral and tricuspid repair through VClip, signaling a broader structural heart pipeline. All of this is promising but comes with the usual development, regulatory, and clinical risks that accompany cutting‑edge medical devices.

Summary

Anteris is an early‑stage structural heart company with a compelling scientific and engineering story, but still at a pre‑commercial, loss‑making stage. Financials show a standard development‑phase profile: no meaningful revenue, ongoing operating losses, negative cash flow, and reliance on equity funding rather than debt. On the strategic side, it is targeting a large and established market with a differentiated, patented valve technology that has shown encouraging early clinical signals. The company’s future hinges on successful execution of pivotal trials, regulatory approvals, and eventual commercial adoption in the face of entrenched competition. This combination creates a profile of high scientific potential and meaningful execution and financing risk, typical of early med‑tech innovators.

NEWS

November 17, 2025 · 6:00 AM UTC

Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves

Read more

November 12, 2025 · 5:52 PM UTC

Anteris Announces Results for the Third Quarter of 2025

Read more

October 27, 2025 · 5:43 PM UTC

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Read more

October 27, 2025 · 8:43 AM UTC

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

Read more

September 19, 2025 · 2:30 AM UTC

Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders

Read more